Another study showed that S100P levels in bile were significantly elevated in patients with CCA, and bile S100P could distinguish between patients with CCA and choledocholithiasis with sensitivity and specificity of 92.9% and 70.0%, respectively (63). This evidence concerns the gene S100P and cholangiocarcinoma.